Invention Grant
![Polymorphic form of N-{6-(hydroxypropan-2-yl)-2-[2-(methylsulphonyl)ethyl]-2H-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide](/docs/US/2020-09-01/US10759758B2/abs.jpg.600x600.jpg)
- Patent Title: Polymorphic form of N-{6-(hydroxypropan-2-yl)-2-[2-(methylsulphonyl)ethyl]-2H-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide
-
Application No.: US16097067Application Date: 2017-04-25
-
Publication No.: US10759758B2Publication Date: 2020-09-01
- Inventor: Tobias Thaler , Johannes Platzek , Nicolas Guimond
- Applicant: Bayer Pharma Aktiengesellschaft
- Applicant Address: DE Berlin
- Assignee: Bayer Pharma Aktiengesellschaft
- Current Assignee: Bayer Pharma Aktiengesellschaft
- Current Assignee Address: DE Berlin
- Agency: Morrison & Foerster LLP
- Priority: com.zzzhc.datahub.patent.etl.us.BibliographicData$PriorityClaim@18f01b9b
- International Application: PCT/EP2017/059767 WO 20170425
- International Announcement: WO2017/186703 WO 20171102
- Main IPC: C07D231/56
- IPC: C07D231/56 ; C07D213/18 ; C07D213/81 ; C07D401/12 ; C07D213/54
![Polymorphic form of N-{6-(hydroxypropan-2-yl)-2-[2-(methylsulphonyl)ethyl]-2H-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide](/abs-image/US/2020/09/01/US10759758B2/abs.jpg.150x150.jpg)
Abstract:
The present invention relates to crystalline forms of N-{6-(2-Hydroxypropan-2-yl)-2-[2-(methylsulphonyl)ethyl]-2H-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide, to processes for their preparation, to pharmaceutical compositions comprising them and to their use in the control of disorders.
Public/Granted literature
Information query
